Disseminated nocardiosis and anti-GM-CSF antibodies.

Anti-GM-CSF autoantibodies Anti-cytokine autoantibodies Immunodeficiency Nocardiosis

Journal

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297

Informations de publication

Date de publication:
20 Feb 2024
Historique:
received: 10 07 2023
accepted: 12 02 2024
medline: 21 2 2024
pubmed: 21 2 2024
entrez: 21 2 2024
Statut: aheadofprint

Résumé

Infections that are unusually severe or caused by opportunistic pathogens are a hallmark of primary immunodeficiency (PID). Anti-cytokine autoantibodies (ACA) are an emerging cause of acquired immunodeficiency mimicking PID. Nocardia spp. are Gram-positive bacteria generally inducing disseminated infections in immunocompromised patients, but seldom also occurring in apparently immunocompetent hosts. Anti-GM-CSF autoantibodies are associated with autoimmune pulmonary alveolar proteinosis (PAP). In those patients, an increased incidence of disseminated nocardiosis and cryptococcosis has been observed. It is unclear whether the PAP or the autoantibodies predispose to the infection. We report an apparently immunocompetent woman presenting with disseminated nocardiosis without any evidence of PAP. Clinical data and radiological images were retrospectively collected. Lymphocyte populations were analyzed by flow cytometry. Anti-GM-CSF autoantibodies were measured by ELISA. A 55-year-old otherwise healthy woman presented with cerebral and pulmonary abscesses. Personal and familial history of infections or autoimmunity were negative. After extensive examinations, a final diagnosis of disseminated nocardiosis was made. Immunologic investigations including neutrophilic function and IFN-γ/IL-12 circuitry failed to identify a PID. Whole-exome sequencing did not find pathogenic variants associated with immunodeficiency. Serum anti-GM-CSF autoantibodies were positive. There were no clinical or instrumental signs of PAP. Trimethoprim-sulfamethoxazole and imipenem were administered, with progressive improvement and recovery of the infectious complication. We identified anti-GM-CSF autoantibodies as the cause of disseminated nocardiosis in a previously healthy and apparently immunocompetent adult. This case emphasizes the importance of including ACA in the differential diagnosis of PID, especially in previously healthy adults. Importantly, anti-GM-CSF autoantibodies can present with disseminated nocardiosis without PAP.

Identifiants

pubmed: 38379052
doi: 10.1007/s10096-024-04785-z
pii: 10.1007/s10096-024-04785-z
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Bousfiha A, Jeddane L, Picard C, Al-Herz W, Ailal F, Chatila T et al (2020) Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification. J Clin Immunol 40:66–81
doi: 10.1007/s10875-020-00758-x pubmed: 32048120 pmcid: 7082388
Margalit I, Goldberg E, Ben Ari Y, Ben-Zvi H, Shostak Y, Krause I et al (2020) Clinical correlates of nocardiosis. Sci Rep 10:14272
doi: 10.1038/s41598-020-71214-4 pubmed: 32868850 pmcid: 7459281
Martínez-Barricarte R (2020) Isolated nocardiosis, an unrecognized primary immunodeficiency? Front Immunol 11:590239
doi: 10.3389/fimmu.2020.590239 pubmed: 33193422 pmcid: 7606290
Ataya A, Knight V, Carey BC, Lee E, Tarling EJ, Wang T (2021) The role of GM-CSF autoantibodies in infection and autoimmune pulmonary alveolar proteinosis: a concise review. Front Immunol 12:752856
doi: 10.3389/fimmu.2021.752856 pubmed: 34880857 pmcid: 8647160
Palterer B, Bartalesi F, Mazzoni A, Maggi L, Provenzano A, Vergoni F et al (2020) Disseminated Mycobacterium xenopi in an adult with IL-12Rβ1 deficiency. J Clin Immunol 40:1166–1170
doi: 10.1007/s10875-020-00848-w pubmed: 32856198
Uchida K, Nakata K, Carey B, Chalk C, Suzuki T, Sakagami T et al (2014) Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis. J Immunol Methods 402:57–70
doi: 10.1016/j.jim.2013.11.011 pubmed: 24275678
Jayaschandran V, Gjorgova-Gjeorgjievski S, Siddique H (2018) Pulmonary nocardiosis in a patient with idiopathic CD4 T-lymphocytopenia: nocardiosis in ICL. Respirol Case Rep 6:e00283
doi: 10.1002/rcr2.283 pubmed: 29321927
Kitamura T, Tanaka N, Watanabe J, Uchida KS, Yamada Y et al (1999) Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 190:875–880
doi: 10.1084/jem.190.6.875 pubmed: 10499925 pmcid: 2195627
Ushach I, Zlotnik A (2016) Biological role of granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid lineage. J Leukocyte Biol 100:481–489
doi: 10.1189/jlb.3RU0316-144R pubmed: 27354413 pmcid: 4982611
Uchida K (2003) High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 103:1089–1098
doi: 10.1182/blood-2003-05-1565 pubmed: 14512323
Dougan M, Dranoff G, Dougan SK (2019) GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation. Immunity 50:796–811
doi: 10.1016/j.immuni.2019.03.022 pubmed: 30995500
Rosen LB, Freeman AF, Yang LM, Jutivorakool K, Olivier KN, Angkasekwinai N et al (2013) Anti–GM-CSF autoantibodies in patients with cryptococcal meningitis. The J Immunol 190:3959–3966
doi: 10.4049/jimmunol.1202526 pubmed: 23509356
Saijo T, Chen J, Chen SC-A, Rosen LB, Yi J, Sorrell TC et al (2014) Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients. mBio 5:e00912–e00914
doi: 10.1128/mBio.00912-14 pubmed: 24643864 pmcid: 3967522
Rosen LB, Rocha Pereira N, Figueiredo C, Fiske LC, Ressner RA, Hong JC et al (2015) Nocardia-induced granulocyte macrophage colony-stimulating factor is neutralized by autoantibodies in disseminated/extrapulmonary nocardiosis. Clin Infect Dis 60:1017–1025
doi: 10.1093/cid/ciu968 pubmed: 25472947
Berthoux C, Mailhe M, Vély F, Gauthier C, Mège J-L, Lagier J-C et al (2021) Granulocyte macrophage colony-stimulating factor-specific autoantibodies and cerebral Nocardia with pulmonary alveolar proteinosis. Open Forum Infect Dis 8:ofaa612
doi: 10.1093/ofid/ofaa612 pubmed: 33614812
Salvator H, Cheng A, Rosen LB, Williamson PR, Bennett JE, Anuj K et al (2022) Neutralizing GM-CSF autoantibodies in pulmonary alveolar proteinosis, cryptococcal meningitis and severe nocardiosis. Respir Res 23:280
doi: 10.1186/s12931-022-02103-9 pubmed: 36221098 pmcid: 9552154
for the NEXUS Study Group, Taylor PC, Saurigny D, Vencovsky J, Takeuchi T, Nakamura T et al (2019) Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial. Arthritis Res Ther 21:101
doi: 10.1186/s13075-019-1879-x pmcid: 6471864
Mortha A, Remark R, Del Valle DM, Chuang L-S, Chai Z, Alves I et al (2022) Neutralizing anti-granulocyte macrophage-colony stimulating factor autoantibodies recognize post-translational glycosylations on granulocyte macrophage-colony stimulating factor years before diagnosis and predict complicated Crohn’s disease. Gastroenterology 163:659–670
doi: 10.1053/j.gastro.2022.05.029 pubmed: 35623454
Toullec L, Batteux F, Santulli P, Chouzenoux S, Jeljeli M, Belmondo T et al (2020) High levels of anti-GM-CSF antibodies in deep infiltrating endometriosis. Reprod Sci 27:211–217
doi: 10.1007/s43032-019-00021-8 pubmed: 32046390
Tazawa R, Ueda T, Abe M, Tatsumi K, Eda R, Kondoh S, Morimoto K, Tanaka T, Yamaguchi E, Takahashi A, Oda M (2020) Inhaled GM-CSF for pulmonary alveolar proteinosis. N Engl J Med 382:197–198
doi: 10.1056/NEJMc1914606

Auteurs

Barbara Brugnoli (B)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Lorenzo Salvati (L)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Nicoletta Di Lauria (N)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.

Annarita Botta (A)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.

Camilla Tozzetti (C)

Internal Medicine Unit 3, Careggi University Hospital, Florence, Italy.

Alessandro Biscarini (A)

Department of Experimental and Clinical Biomedical Sciences, Radiodiagnostic Unit n. 2, University of Florence-Careggi University Hospital, Florence, Italy.

Manuela Capone (M)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Filomena Ferrentino (F)

Internal Medicine Unit 3, Careggi University Hospital, Florence, Italy.

Chiara Naldi (C)

Internal Medicine Unit 3, Careggi University Hospital, Florence, Italy.

Giovanni Ascione (G)

Internal Medicine Unit 3, Careggi University Hospital, Florence, Italy.

Alessio Mazzoni (A)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Flow Cytometry Diagnostic Center and Immunotherapy, Careggi University Hospital, Florence, Italy.

Laura Maggi (L)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Ilaria Campo (I)

Pneumology Unit, Internal Medicine and Infectious Diseases Department, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

Brenna Carey (B)

Translational Pulmonary Science Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Bruce Trapnell (B)

Translational Pulmonary Science Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Francesco Liotta (F)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Immunology and Cell Therapy Unit, Careggi University Hospital, Florence, Italy.

Lorenzo Cosmi (L)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Immunoallergology Unit, Careggi University Hospital, Florence, Italy.

Alessandro Bartoloni (A)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.

Francesco Annunziato (F)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Immunology and Cell Therapy Unit, Careggi University Hospital, Florence, Italy.

Paola Parronchi (P)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Immunology and Cell Therapy Unit, Careggi University Hospital, Florence, Italy.

Boaz Palterer (B)

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. boaz.palterer@unifi.it.
Flow Cytometry Diagnostic Center and Immunotherapy, Careggi University Hospital, Florence, Italy. boaz.palterer@unifi.it.

Classifications MeSH